Logotype for Sutro Biopharma Inc

Sutro Biopharma (STRO) investor relations material

Sutro Biopharma Piper Sandler 37th Annual Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Sutro Biopharma Inc
Piper Sandler 37th Annual Healthcare Conference summary3 Dec, 2025

Platform innovation and pipeline progress

  • XpressCF platform enables site-specific conjugation and higher ADC drug exposure, optimizing antibody, linker, and payload for improved performance and safety.

  • Dual payload ADCs are being developed to overcome resistance seen with single payload ADCs, aiming for best-in-class therapies.

  • The pipeline includes single and dual payload ADCs targeting complex, high-value oncology indications with large market opportunities.

  • Partnerships, such as with Astellas, focus on immunostimulatory ADCs and dual payload constructs.

  • Three INDs are planned over the next three years, with one already filed for STRO-004.

Clinical development and trial updates

  • STRO-004, a tissue factor ADC, is in phase I with rapid enrollment and strong investigator enthusiasm due to a robust preclinical package.

  • The program is designed for high safety and efficacy, with a DAR8 Exatecan payload and advanced linker technology.

  • High safety margin demonstrated with HNSTD of 50 mg/kg and anti-tumor activity at low doses in PDX models.

  • Top-line data for STRO-004 expected by mid-next year.

  • The program aims to expand beyond cervical cancer into pancreatic, lung, head and neck, and colorectal cancers.

Future plans and financial outlook

  • IND for integrin beta-6 ADC (STRO-006) planned for next year, targeting non-small cell lung cancer and other indications.

  • Dual payload ADC STRO-227 targets PTK7, aiming to address efficacy and safety limitations of prior single payload approaches.

  • Immunostimulatory ADCs with Astellas combine cytotoxic and immune-activating agents, with the first clinical program expected early next year.

  • Cash runway extended to mid-2027, with potential for further extension through partnerships and milestones.

  • The company expects to have three more programs in the clinic next year, becoming a multi-program clinical oncology company.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Sutro Biopharma earnings date

Logotype for Sutro Biopharma Inc
Q4 202527 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Sutro Biopharma earnings date

Logotype for Sutro Biopharma Inc
Q4 202527 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Sutro Biopharma Inc. is a biotechnology company specializing in the discovery, development, and manufacturing of therapeutics aimed at treating cancer. The company leverages its proprietary cell-free protein synthesis platform, XpressCF, to design and produce novel, targeted antibody-drug conjugates (ADCs), bispecific antibodies, and other protein therapeutics. Sutro's focus is on creating therapies that precisely target and eliminate cancer cells while minimizing damage to healthy tissues, advancing treatment options for patients with difficult-to-treat cancers. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage